Thank you Madrigal for your support on this FAQ Video Module.

In this insightful video, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, breaks down the current understanding of disease progression in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Dr. Brown reviews the estimated timelines—from simple steatosis to inflammation and fibrosis, and ultimately cirrhosis—and highlights key risk factors including age, type 2 diabetes, uncontrolled metabolic conditions, genetic predisposition, and alcohol use. She also reviews guidance from the AASLD on fibrosis reassessment timelines and explains why identifying "fast progressors" remains a clinical challenge. Watch now to gain practical insights into monitoring fibrosis progression, interpreting risk factors, and determining when intensified follow-up or treatment may be warranted.